Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-19-000337
Filing Date
2019-05-06
Accepted
2019-05-06 17:30:22
Documents
1
Period of Report
2019-05-02

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 10857
  Complete submission text file 0000947871-19-000337.txt   13092
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Issuer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel GP Ltd. (Reporting) CIK: 0001569590 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-36620 | Film No.: 19800495

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Reporting) CIK: 0001569821 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-36620 | Film No.: 19800496